8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 3, 2010

Shire plc

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486

(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

________________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01.  Other Events

     Shire plc has issued the press release attached hereto as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

                 (d)  Exhibits.  The following exhibit is filed herewith:

99.01         Press Release dated March 3, 2010

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
	Name:	Angus Russell
	Title:	Chief Executive Officer

Dated: March 3, 2010

EXHIBIT INDEX
Number	Description
99.01	Press Release dated March 3, 2010

EX-99.1

Exhibit 99.01

Press Release www.shire.com

Director/PDMR Shareholding

March 3, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,announces that on March 1, 2010 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire Portfolio Share Plan (the “Plan”).

Awards of Stock Appreciation Rights (“SARs”) under Part A of the Plan

Name of PDMR	Type of Security	No of Ordinary Shares or ADSs	Exercise price
Angus Russell (Executive Director)*	ADSs	105,616	$64.91
Graham Hetherington (Executive Director)*	Ordinary Shares	134,814	£14.43
Tatjana May	Ordinary Shares	38,000	£14.43
Michael Cola	ADSs	20,000	$64.91
Sylvie Gregoire	ADSs	20,000	$64.91
Barbara Deptula	ADSs	12,333	$64.91
Anita Graham	ADSs	11,333	$64.91

*Vesting of awards to Executive Directors is subject to performance targets

SARs will normally vest after three years, subject to any performance targets having been satisfied.  Vested SARs will be capable of exercise for a period of four years.  The four year exercise period is subject to shareholder approval at Shire plc’s 2010 Annual General Meeting.  Should such approval not be obtained, the exercise period will be two years.  No consideration was paid for the grant of the SARs.

Performance Share Awards (“PSA Awards”) under Part B of the Plan

Name of PDMR	Type of Security	No of Ordinary Shares or ADSs	Market value
Angus Russell (Executive Director)*	ADSs	73,948	$64.91
Graham Hetherington (Executive Director)*	Ordinary Shares	98,864	£14.43
Tatjana May	Ordinary Shares	28,000	£14.43
Michael Cola	ADSs	15,000	$64.91
Sylvie Gregoire	ADSs	15,000	$64.91
Barbara Deptula	ADSs	9,000	$64.91
Anita Graham	ADSs	8,000	$64.91

*Vesting of awards to Executive Directors is subject to performance targets

The PSA Awards will normally vest after three years, subject to any performance targets being satisfied.  Once vested, sufficient ordinary shares or ADSs will be transferred or allotted to the participant within 30 days.  No consideration was paid for the grant of the PSA Awards.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 617 551 9715

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.